Masimo (NASDAQ: MASI) Signal Extraction Technology® (SET®) pulse oximetry, known for its industry-leading accuracy and clinical validation, continues to set the standard in overcoming the limitations of conventional pulse oximetry. As of 2024, Masimo SET® is the primary pulse oximetry technology at all ten top U.S. hospitals and is used to monitor over 200 million patients annually worldwide. Backed by more than 100 studies proving its superior performance, SET® delivers the highest SpO2 accuracy, especially in challenging conditions like patient motion, low perfusion, and across all skin tones. Masimo’s expertise has extended the application of SET® beyond traditional hospital settings to include tetherless sensors, wearable devices for home use, baby monitors, and opioid overdose monitoring solutions, enhancing patient care across various environments.
Superior Performance
Masimo SET® was born from Founder and CEO Joe Kiani’s mission to accurately and reliably monitor oxygen saturation in neonatal infants, a challenge that traditional pulse oximetry struggled to overcome due to frequent movement and poor perfusion. SET® successfully addressed these challenges, and Masimo continues to push the boundaries of accuracy and reliability.
Masimo SET® excels during motion. Before SET®, high false alarm rates were common due to motion and low perfusion. Masimo SET® reduced false alarms by more than 80% while significantly improving true alarm detection.
Masimo SET® excels during low perfusion. A recent peer-reviewed study found that Masimo SET® SpO2 accuracy (ARMS*) was 1.37% in subjects with normal perfusion and 1.64% in those with low perfusion.
Masimo SET® excels on dark skin. A peer-reviewed publication showed only a 0.15% difference in bias between dark- and light-skinned subjects using Masimo RD SET sensors, which is not clinically significant. The sensors accurately measured SpO2 for both Black and White subjects, even during low perfusion.
Improved Outcomes
Masimo SET® revolutionized pulse oximetry, transforming it into a clinically valuable tool. Before SET®, no study had demonstrated that pulse oximetry improved patient outcomes despite its widespread use. Masimo SET® has had a profound impact on patients’ lives, clinician workflows, hospital finances, and even environmental sustainability.
Masimo SET® saves lives. A 10-year study of general floor patients monitored with Masimo SET® after surgery found zero preventable deaths or brain damage from opioid-induced respiratory depression. Another study showed an 80% reduction in retinopathy of prematurity (ROP) rates using SET®. Additionally, in studies involving over 300,000 newborns, SET® significantly improved the sensitivity of screening for critical congenital heart disease (CCHD).
Masimo SET® saves time. SET® produces 86% fewer false alarms than competitor technologies, and its use on general floor patients led to a 60% reduction in rapid response team activations without compromising patient safety.
Masimo SET® saves the environment. By incorporating Masimo’s unique replacement tape, SET® reduced single-patient-use sensor volume by 60%, and RD SET® sensors produce 84% less waste compared to traditional sensors. Masimo is also the first pulse oximetry manufacturer to earn the “Greenhealth approved” sustainability seal from Practice Greenhealth.
Masimo SET® saves money. One hospital saved $7 million over 12 years by using a replacement tape sensor management strategy with Masimo SET®. Another facility saw a 50% reduction in unplanned ICU transfers when using SET® to monitor med-surg patients. Additionally, Masimo SET® and rainbow® technologies could potentially save a 250-bed hospital over $4 million annually.
“Without SET®, there would be no rainbow® SpHb® or ORi™, no Hospital Automation™ products like Root®, Patient SafetyNet™, or Radius VSM™, and no telemonitoring solutions like Masimo SafetyNet® or Masimo W1®,” said Joe Kiani. “Masimo was founded to solve the limitations of noninvasive monitoring—problems once thought unsolvable. We’re honored to be the choice of all top ten U.S. hospitals, but we are not satisfied. We remain committed to advancing our legacy of innovation and improving lives worldwide.”
